Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Iyer 2008 Nature Precedings"

From Bioblast
 
(9 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{Publication
{{Publication
|title=Iyer S, Thomas R, Portell F, Dunham L, Quigley C, Bennett JP (2008) Recombinant mitochondrial transcription factor A with N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression in G11778A leber’s hereditary optic neuropathy cybrid cells. Nature Precedings : hdl:10101/npre.2008.2084.1
|title=Iyer S, Thomas R, Portell F, Dunham L, Quigley C, Bennett JP (2008) Recombinant mitochondrial transcription factor A with N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression in G11778A leber’s hereditary optic neuropathy cybrid cells. Nature Precedings: hdl:10101/npre.2008.2084.1
|info=[http://precedings.nature.com/documents/2084/version/1/files/npre20082084-1.pdf Nature Precedings : hdl:10101/npre.2008.2084.1]
|info=[http://precedings.nature.com/documents/2084/version/1/files/npre20082084-1.pdf Nature Precedings : hdl:10101/npre.2008.2084.1]
|authors=Iyer S, Thomas R, Portell F, Dunham L, Quigley C, Bennett JP
|authors=Iyer Shilpa, Thomas R, Portell F, Dunham L, Quigley C, Bennett JP
|year=2008
|year=2008
|journal=Nature Prec.
|journal=Nature Precedings
|abstract=Diseases involving mitochondrial defects usually manifest themselves in highenergy, post-mitotic tissues such as brain, retina, skeletal and cardiac muscle and frequently cause deficiencies in mitochondrial bioenergetics1, 2. We have developed a scalable procedure to produce recombinant human mitochondrial transcription factor A (TFAM) 3-5 modified with an N-terminal protein transduction domain (PTD)6 and mitochondrial localization signal (MLS) that allow it to cross membranes and enter mitochondria through its “mitochondrial transduction domain” (MTD,=PTD+MLS). In vitro studies in a classic mitochondrial disease cell model demonstrated that Alexa488-labeled MTD-TFAM rapidly entered the mitochondrial compartment. MTD-TFAM treatment of these cell lines reversibly increased oxygen consumption (respiration) rates 3-fold, levels of respiratory proteins and mitochondrial gene expression. In vivo results demonstrated that respiration increased to lesser degrees in mitochondria from tissues of mice injected with MTD-TFAM. MTD-TFAM can alter mitochondrial bioenergetics and holds promise for treatment of mitochondrial diseases involving deficiencies of energy production.
|abstract=Diseases involving mitochondrial defects usually manifest themselves in highenergy, post-mitotic tissues such as brain, retina, skeletal and cardiac muscle and frequently cause deficiencies in mitochondrial bioenergetics1, 2. We have developed a scalable procedure to produce recombinant human mitochondrial transcription factor A (TFAM) 3-5 modified with an N-terminal protein transduction domain (PTD)6 and mitochondrial localization signal (MLS) that allow it to cross membranes and enter mitochondria through its “mitochondrial transduction domain” (MTD,=PTD+MLS). In vitro studies in a classic mitochondrial disease cell model demonstrated that Alexa488-labeled MTD-TFAM rapidly entered the mitochondrial compartment. MTD-TFAM treatment of these cell lines reversibly increased oxygen consumption (respiration) rates 3-fold, levels of respiratory proteins and mitochondrial gene expression. In vivo results demonstrated that respiration increased to lesser degrees in mitochondria from tissues of mice injected with MTD-TFAM. MTD-TFAM can alter mitochondrial bioenergetics and holds promise for treatment of mitochondrial diseases involving deficiencies of energy production.
|keywords=TFAM, Respiration, Mitochondrial gene expression, Respiratory proteins
|keywords=TFAM, Respiration, Mitochondrial gene expression, Respiratory proteins
|mipnetlab=US_VA Richmond_Bennett JP
|mipnetlab=US_VA Richmond_Bennett JP, US VA Richmond Iyer S
|discipline=Mitochondrial Physiology, Biomedicine
|discipline=Mitochondrial Physiology, Biomedicine
}}
}}
{{Labeling
{{Labeling
|instruments=Oxygraph-2k, Theory
|area=Respiration, Genetic knockout;overexpression, mt-Medicine
|injuries=Genetic Defect; Knockdown; Overexpression
|tissues=Nervous system
|tissues=Neurons; Brain
|diseases=Inherited
|topics=Respiration; OXPHOS; ETS Capacity
|couplingstates=OXPHOS
|instruments=Oxygraph-2k
|discipline=Mitochondrial Physiology, Biomedicine
|discipline=Mitochondrial Physiology, Biomedicine
}}
}}

Latest revision as of 16:33, 6 May 2020

Publications in the MiPMap
Iyer S, Thomas R, Portell F, Dunham L, Quigley C, Bennett JP (2008) Recombinant mitochondrial transcription factor A with N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression in G11778A leber’s hereditary optic neuropathy cybrid cells. Nature Precedings: hdl:10101/npre.2008.2084.1

» Nature Precedings : hdl:10101/npre.2008.2084.1

Iyer Shilpa, Thomas R, Portell F, Dunham L, Quigley C, Bennett JP (2008) Nature Precedings

Abstract: Diseases involving mitochondrial defects usually manifest themselves in highenergy, post-mitotic tissues such as brain, retina, skeletal and cardiac muscle and frequently cause deficiencies in mitochondrial bioenergetics1, 2. We have developed a scalable procedure to produce recombinant human mitochondrial transcription factor A (TFAM) 3-5 modified with an N-terminal protein transduction domain (PTD)6 and mitochondrial localization signal (MLS) that allow it to cross membranes and enter mitochondria through its “mitochondrial transduction domain” (MTD,=PTD+MLS). In vitro studies in a classic mitochondrial disease cell model demonstrated that Alexa488-labeled MTD-TFAM rapidly entered the mitochondrial compartment. MTD-TFAM treatment of these cell lines reversibly increased oxygen consumption (respiration) rates 3-fold, levels of respiratory proteins and mitochondrial gene expression. In vivo results demonstrated that respiration increased to lesser degrees in mitochondria from tissues of mice injected with MTD-TFAM. MTD-TFAM can alter mitochondrial bioenergetics and holds promise for treatment of mitochondrial diseases involving deficiencies of energy production. Keywords: TFAM, Respiration, Mitochondrial gene expression, Respiratory proteins

O2k-Network Lab: US_VA Richmond_Bennett JP, US VA Richmond Iyer S


Labels: MiParea: Respiration, Genetic knockout;overexpression, mt-Medicine  Pathology: Inherited 


Tissue;cell: Nervous system 


Coupling state: OXPHOS 

HRR: Oxygraph-2k